Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 20Plasma cell 2Dermatologic 1

Conditions

Multiple Myeloma 2123Neoplasms, Plasma Cell 505Lymphoma 355Lymphoma, Non-Hodgkin 334Hodgkin Disease 329Leukemia, Lymphocytic, Chronic, B-Cell 307Precursor Cell Lymphoblastic Leukemia-Lymphoma 299Leukemia 290Leukemia, Myeloid, Acute 270Myelodysplastic Syndromes 263Lymphoma, Mantle-Cell 228Lymphoma, Follicular 224Lymphoma, Large B-Cell, Diffuse 216Lymphoma, B-Cell, Marginal Zone 206Burkitt Lymphoma 201Recurrence 188Myeloproliferative Disorders 182Lymphoma, Large-Cell, Immunoblastic 182Immunoglobulin Light-chain Amyloidosis 163Primary Myelofibrosis 153Leukemia, Myeloid, Chronic-Phase 152Leukemia, Myeloid, Accelerated Phase 143Lymphoma, T-Cell, Cutaneous 140Leukemia, Myelomonocytic, Chronic 133Blast Crisis 131Mycosis Fungoides 126Sezary Syndrome 125Congenital Abnormalities 122Waldenstrom Macroglobulinemia 121Leukemia, Hairy Cell 110

Interventions

selinexor 1pazopanib 1fludarabine 1Proton Therapy 1Ifosfamide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Liposarcoma, Myxoid × Plasma cell × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

University of Pennsylvania

Phase 1 Terminated
3 enrolled
DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡